Thrombolysis Endovascular Treatment of Pulmonary Embolism

The patients with right ventricular dysfunction who are diagnosed by CT pulmonary angiography will receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the in this study. The Change of RV to LV Diameter Ratio,Rate of death,rate of major bleeding,pulmonary embolism recurrence at 1month will be reviewed to assess the efficacy and safety.

Inclusion criteria

• CT evidence of proximal PE
• Age ≥ 18 years
• Pulmonary embolism symptom duration ≤14 days
• Massive PE (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated cardiac arrest) OR Submassive PE (RV diameter-to-LV diameter ≥ 0.9 on contrast-enhanced chest CT)

Exclusion criteria

• Age <18 years
• PE symptom duration >14 days
• Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year
• Recent (within one month) or active bleeding from a major organ
• Pregnancy
• Chronic pulmonary hypertension or severe chronic obstructive pulmonary disease
• Administration of thrombolytic agents within the previous 3 days
• Life expectancy < 30 days
• Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated
• Inability to follow protocol requirements